ES2880347T3 - Derivados de tiazol útiles como inhibidores de IDH1 mutante para el tratamiento del cáncer - Google Patents
Derivados de tiazol útiles como inhibidores de IDH1 mutante para el tratamiento del cáncer Download PDFInfo
- Publication number
- ES2880347T3 ES2880347T3 ES17735296T ES17735296T ES2880347T3 ES 2880347 T3 ES2880347 T3 ES 2880347T3 ES 17735296 T ES17735296 T ES 17735296T ES 17735296 T ES17735296 T ES 17735296T ES 2880347 T3 ES2880347 T3 ES 2880347T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- salt
- cancer
- formula
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 B*C(C(*)[C@@]1C(*)=C(C)N2*)C1C2=O Chemical compound B*C(C(*)[C@@]1C(*)=C(C)N2*)C1C2=O 0.000 description 2
- RCCBICVGYKSAFH-UHFFFAOYSA-N CCc(ccc(N(C)C)c1)c1N Chemical compound CCc(ccc(N(C)C)c1)c1N RCCBICVGYKSAFH-UHFFFAOYSA-N 0.000 description 1
- VXXZMNMCLGPMRK-UHFFFAOYSA-N CNc(cc1)cc(N)c1Cl Chemical compound CNc(cc1)cc(N)c1Cl VXXZMNMCLGPMRK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662353298P | 2016-06-22 | 2016-06-22 | |
| PCT/US2017/038549 WO2017223202A1 (en) | 2016-06-22 | 2017-06-21 | Thiazole derivatives useful as mutant idh1 inhibitors for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2880347T3 true ES2880347T3 (es) | 2021-11-24 |
Family
ID=59276859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17735296T Active ES2880347T3 (es) | 2016-06-22 | 2017-06-21 | Derivados de tiazol útiles como inhibidores de IDH1 mutante para el tratamiento del cáncer |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10836759B2 (enExample) |
| EP (1) | EP3475276B1 (enExample) |
| JP (1) | JP6987798B2 (enExample) |
| CN (1) | CN109641887B (enExample) |
| AU (1) | AU2017281088B2 (enExample) |
| CA (1) | CA3028999A1 (enExample) |
| ES (1) | ES2880347T3 (enExample) |
| WO (1) | WO2017223202A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10005734B2 (en) | 2014-09-19 | 2018-06-26 | Forma Therapeutics, Inc. | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| JP6751081B2 (ja) | 2014-09-19 | 2020-09-02 | フォーマ セラピューティクス，インコーポレイテッド | 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジニルキノリノン誘導体 |
| HUE062424T2 (hu) | 2014-09-19 | 2023-11-28 | Forma Therapeutics Inc | Piridin-2(1H)-on kinolinon származékok mint mutáns izocitrát dehidrogenáz inhibitorok |
| EP3194383B1 (en) | 2014-09-19 | 2019-11-06 | Forma Therapeutics, Inc. | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors |
| WO2016171756A1 (en) | 2015-04-21 | 2016-10-27 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
| US10294206B2 (en) | 2015-04-21 | 2019-05-21 | Forma Tm2, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| WO2019222553A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Inhibiting mutant idh-1 |
| US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
| US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| US10532047B2 (en) | 2018-05-16 | 2020-01-14 | Forma Therapeutics, Inc. | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6067226B2 (ja) * | 2009-03-13 | 2017-01-25 | アジオス ファーマシューティカルズ， インコーポレイテッド | 細胞増殖関連疾患のための方法および組成物 |
| AU2010229968A1 (en) | 2009-03-24 | 2011-10-13 | Gilead Calistoga Llc | Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
| MX2015012822A (es) * | 2013-03-14 | 2016-05-31 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante. |
| EP3237385B1 (en) * | 2014-12-22 | 2021-11-24 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Mutant idh1 inhibitors useful for treating cancer |
-
2017
- 2017-06-21 JP JP2018567108A patent/JP6987798B2/ja active Active
- 2017-06-21 US US16/312,206 patent/US10836759B2/en active Active
- 2017-06-21 CA CA3028999A patent/CA3028999A1/en active Pending
- 2017-06-21 EP EP17735296.0A patent/EP3475276B1/en active Active
- 2017-06-21 WO PCT/US2017/038549 patent/WO2017223202A1/en not_active Ceased
- 2017-06-21 ES ES17735296T patent/ES2880347T3/es active Active
- 2017-06-21 AU AU2017281088A patent/AU2017281088B2/en active Active
- 2017-06-21 CN CN201780051410.0A patent/CN109641887B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109641887B (zh) | 2022-09-20 |
| EP3475276B1 (en) | 2021-03-31 |
| CN109641887A (zh) | 2019-04-16 |
| JP2019518770A (ja) | 2019-07-04 |
| AU2017281088B2 (en) | 2021-05-27 |
| AU2017281088A1 (en) | 2019-01-17 |
| WO2017223202A1 (en) | 2017-12-28 |
| US20190241551A1 (en) | 2019-08-08 |
| US10836759B2 (en) | 2020-11-17 |
| JP6987798B2 (ja) | 2022-01-05 |
| CA3028999A1 (en) | 2017-12-28 |
| EP3475276A1 (en) | 2019-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2880347T3 (es) | Derivados de tiazol útiles como inhibidores de IDH1 mutante para el tratamiento del cáncer | |
| ES2905564T3 (es) | Inhibidores mutantes de IDH1 útiles para tratar el cáncer | |
| KR102288281B1 (ko) | Fgfr4 억제제, 이의 제조 방법 및 약학적 응용 | |
| US9187474B2 (en) | Raf inhibitor compounds | |
| EP2604610B1 (en) | Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof | |
| CN104936945B (zh) | 吡啶酮类衍生物、其制备方法及其在医药上的应用 | |
| KR102359993B1 (ko) | 피리미도[5,4-b]인돌리진 또는 피리미도[5,4-b]피롤리진 화합물, 그의 제조방법 및 용도 | |
| JP5583698B2 (ja) | プロテインキナーゼａｂｌおよびｓｒｃの阻害剤としてのアザインドール誘導体 | |
| BR112016001328B1 (pt) | Compostos derivados de indolizina, composição farmacêutica e combinação que os compreendem, seus usos e processo para a preparação dos mesmos | |
| CA2983040C (en) | Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof | |
| CN103804292A (zh) | Hdm2和hdmx双重抑制剂3－腈基喹啉衍生物及其制备方法与应用 | |
| JP6386585B2 (ja) | プロテインキナーゼのインヒビターとしてのフロピリジン | |
| TW201900644A (zh) | Fgfr4抑制劑及其制備與應用 | |
| AU2020404978A1 (en) | CD206 modulators their use and methods for preparation | |
| CN115215883A (zh) | Usp7抑制剂 | |
| TWI548637B (zh) | 酞嗪酮類衍生物、其製備方法及其在醫藥上的應用 |